Balaxi Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Balaxi Pharmaceuticals has been growing earnings at an average annual rate of 3%, while the Healthcare industry saw earnings growing at 22.7% annually. Revenues have been growing at an average rate of 21.5% per year. Balaxi Pharmaceuticals's return on equity is 16.5%, and it has net margins of 13.5%.
Key information
3.0%
Earnings growth rate
-0.5%
EPS growth rate
| Healthcare Industry Growth | 29.4% |
| Revenue growth rate | 21.5% |
| Return on equity | 16.5% |
| Net Margin | 13.5% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Balaxi Pharmaceuticals (NSE:BALAXI) Strong Profits May Be Masking Some Underlying Issues
Nov 13
These 4 Measures Indicate That Balaxi Pharmaceuticals (NSE:BALAXI) Is Using Debt Reasonably Well
Jul 30Balaxi Pharmaceuticals Limited's (NSE:BALAXI) Share Price Could Signal Some Risk
May 29Market Might Still Lack Some Conviction On Balaxi Pharmaceuticals Limited (NSE:BALAXI) Even After 38% Share Price Boost
Feb 10Balaxi Pharmaceuticals (NSE:BALAXI) Has A Pretty Healthy Balance Sheet
Feb 09Is Balaxi Pharmaceuticals (NSE:BALAXI) A Risky Investment?
Aug 08The Trend Of High Returns At Balaxi Pharmaceuticals (NSE:BALAXI) Has Us Very Interested
May 20A Look At The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Feb 03Calculating The Intrinsic Value Of Balaxi Pharmaceuticals Limited (NSE:BALAXI)
Sep 06Balaxi Pharmaceuticals (NSE:BALAXI) Knows How To Allocate Capital Effectively
Jun 03Is Weakness In Balaxi Pharmaceuticals Limited (NSE:BALAXI) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?
Mar 12Is Balaxi Pharmaceuticals Limited's(NSE:BALAXI) Recent Stock Performance Tethered To Its Strong Fundamentals?
Nov 27
Revenue & Expenses Breakdown
How Balaxi Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,636 | 356 | 741 | 0 |
| 30 Jun 24 | 2,410 | 454 | 663 | 0 |
| 31 Mar 24 | 2,413 | -24 | 657 | 0 |
| 31 Dec 23 | 2,621 | -52 | 605 | 0 |
| 30 Sep 23 | 2,879 | -106 | 623 | 0 |
| 30 Jun 23 | 3,196 | -95 | 688 | 0 |
| 31 Mar 23 | 3,364 | 460 | 727 | 0 |
| 31 Dec 22 | 3,449 | 506 | 751 | 0 |
| 30 Sep 22 | 3,200 | 545 | 627 | 0 |
| 30 Jun 22 | 3,038 | 511 | 466 | 0 |
| 31 Mar 22 | 2,794 | 477 | 312 | 0 |
| 31 Dec 21 | 2,416 | 433 | 209 | 0 |
| 30 Sep 21 | 2,457 | 421 | 184 | 0 |
| 30 Jun 21 | 2,373 | 401 | 177 | 0 |
| 31 Mar 21 | 2,313 | 381 | 161 | 0 |
| 31 Dec 20 | 1,939 | 312 | 73 | 0 |
| 30 Sep 20 | 1,411 | 228 | 56 | 0 |
| 30 Jun 20 | 938 | 138 | 36 | 0 |
| 31 Mar 20 | 456 | 61 | 46 | 0 |
| 31 Dec 19 | 416 | 53 | 18 | 0 |
| 30 Sep 19 | 342 | 40 | 17 | 0 |
| 30 Jun 19 | 230 | 31 | 13 | 0 |
| 31 Mar 19 | 140 | 20 | 10 | 0 |
| 31 Dec 18 | 79 | 11 | 6 | 0 |
| 30 Sep 18 | 15 | -3 | 3 | 0 |
| 30 Jun 18 | 0 | -8 | 2 | 0 |
| 31 Mar 18 | 0 | -8 | 2 | 0 |
| 31 Dec 17 | -6 | -12 | 1 | 0 |
| 30 Sep 17 | -6 | -11 | 1 | 0 |
| 30 Jun 17 | -6 | -8 | 1 | 0 |
| 31 Mar 17 | 0 | -2 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 1 | 0 |
| 30 Jun 16 | 0 | -1 | 1 | 0 |
| 31 Mar 16 | 0 | -1 | 1 | 0 |
| 31 Dec 15 | 2 | -1 | 1 | 0 |
| 31 Mar 15 | 2 | 1 | 0 | 0 |
| 31 Mar 14 | 2 | 1 | 0 | 0 |
Quality Earnings: BALAXI has a high level of non-cash earnings.
Growing Profit Margin: BALAXI became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BALAXI's earnings have grown by 3% per year over the past 5 years.
Accelerating Growth: BALAXI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: BALAXI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Healthcare industry (29.6%).
Return on Equity
High ROE: BALAXI's Return on Equity (16.5%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 21:05 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Balaxi Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|